TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.

We established two human prostate cancer cell lines, MDA PCa 2a and MDA PCa 2b, the TabBO model system, that reflect common features of human androgen-independent prostate cancer that are not present in other model systems: bone origin, prostate-specific antigen production, androgen receptor expression, and androgen sensitivity. We therefore hypothesized that molecular pathways in our model system reflect common alterations responsible for the progression of a subset of human prostate cancer. Progression to androgen independence has been hypothesized to be largely associated with impairment of the regulation of cell growth or apoptosis of prostate cancer cells. Therefore, in this study, we examined molecular markers known or suspected to be important in prostate cancer progression and key regulators of cell growth and apoptosis: p53, p21WAF1/CIP1, Bcl-2, Bax, retinoblastoma (Rb), and p16INK4A/MITS1. We analyzed the expression of these markers in the cell lines, their tumor of origin, and tumors derived from the cell lines by s.c. inoculation into nude mice. DNA sequencing of the entire open reading frames of the p53 and p21 genes revealed no mutations. Additionally, accumulation of the p53 protein was not found by Western blot analysis, nor was overexpression of the Bcl-2 oncoprotein detected. Bax expression was detected in MDA PCa 2a cells, whereas it was absent in MDA PCa 2b. Rb and p16 protein expression was normal as measured by both Western blot and immunochemical analyses. Immunohistochemical studies of p53, p21, Bcl-2, and Rb in both samples from the original human cancer from which the lines were derived and mouse xenografts derived from the lines revealed similar levels of protein. These results are consistent with reports indicating that 40-50% of bone metastases of prostate cancer have wild-type p53, 50-70% do not overexpress the Bcl-2 protein, and mutations in the p21 gene are rare. Therefore, we conclude that MDA PCa 2a and MDA PCa 2b reflect molecular pathways in a common subset of human androgen-independent prostate cancer and that important molecular players in apoptosis (namely, p53 and Bcl-2) seem to be intact in this subset of androgen-independent prostate cancer. Understanding the signal-transduction pathways operating in these cell lines may help to identify therapeutic targets for prostate cancer.

[1]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  L. Strong,et al.  Exclusion of a p53 germline mutation in a classic Li-Fraumeni syndrome family , 1998, Human Genetics.

[4]  T. McDonnell,et al.  Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo. , 1998, International journal of molecular medicine.

[5]  C. Borner,et al.  Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c , 1998, Nature.

[6]  D. Johnston,et al.  Establishment of two human prostate cancer cell lines derived from a single bone metastasis. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[8]  S. Korsmeyer,et al.  Bax suppresses tumorigenesis and stimulates apoptosis in vivo , 1997, Nature.

[9]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[10]  T. McDonnell,et al.  Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. , 1997, The Journal of urology.

[11]  D. McConkey,et al.  Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. , 1996, Cancer research.

[12]  W. Benedict,et al.  Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro. , 1996, Oncogene.

[13]  J. Brooks,et al.  An uncertain role for p53 gene alterations in human prostate cancers. , 1996, Cancer research.

[14]  H. Scher,et al.  Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. , 1996, International journal of oncology.

[15]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[16]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  M. Oren,et al.  Specific loss of apoptotic but not cell‐cycle arrest function in a human tumor derived p53 mutant. , 1996, The EMBO journal.

[18]  K. Vousden,et al.  p53 in signaling checkpoint arrest or apoptosis. , 1996, Current opinion in genetics & development.

[19]  T. Tammela,et al.  Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. , 1995, The American journal of pathology.

[20]  H. Klocker,et al.  Mutant androgen receptors in prostatic tumors distinguish between amino‐acid‐sequence requirements for transactivation and ligand binding , 1995, International journal of cancer.

[21]  D. Grignon,et al.  Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. , 1995, Oncogene.

[22]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[23]  P. Scardino,et al.  Association of p53 mutations with metastatic prostate cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  H. Klocker,et al.  Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[25]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[26]  W. Catalona,et al.  Management of cancer of the prostate. , 1994, The New England journal of medicine.

[27]  C. Cordon-Cardo,et al.  Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. , 1994, The Journal of urology.

[28]  C. Croce,et al.  Down-regulation of bcl-2 by p53 in breast cancer cells. , 1994, Cancer research.

[29]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[30]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[31]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[32]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[33]  R. Gittes.  Carcinoma of the prostate. , 1991, The New England journal of medicine.

[34]  H. Saya,et al.  Codon 72 polymorphism of the TP53 gene. , 1990, Nucleic acids research.

[35]  T. McDonnell,et al.  bcl-2 expression confers androgen independence in androgen sensitive prostatic carcinoma. , 1997, International journal of oncology.

[36]  E. Gelmann,et al.  p53 oncogene mutations in three human prostate cancer cell lines , 1993, The Prostate.

[37]  N. Kyprianou,et al.  Programmed cell death as a new target for prostatic cancer therapy. , 1991, Cancer surveys.

[38]  W. Benedict,et al.  The retinoblastoma susceptibility gene product: a characteristic pattern in normal cells and abnormal expression in malignant cells. , 1989, Oncogene.